Search Results for “EC” – Page 588 – media

FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. Additionally, the FDA has granted fast track designation for fremanezumab for the prevention of cluster headache.
- Source: finance.yahoo
- 566
- December 19, 2017
cluster headache FDA fremanezumab migraine New Approvals Teva
Novartis-backed resTORbio raises $40M for aging disease trials

Boston biotech resTORbio has pocketed another $40 million from a second-round financing that it hopes gives it enough cash to move its lead candidate for respiratory tract infections in elderly patients into phase 3.
- Source: Fiercebiotech
- 616
- December 19, 2017
financing immune system Market Views Novartis
No interventions proven to prevent late-life dementia

There is no proven intervention for preventing late-life dementia. Researchers from the Minnesota Evidence-based Practice Center (EPC) reviewed published research to determine if physical activity, prescription medications, over-the-counter vitamins and supplements, or cognitive training interventions could help to prevent dementia in patients who did not have it at the time of the studies. The vast majority of research showed that none of the interventions worked. Findings from four systematic evidence reviews are published in Annals of Internal Medicine.
- Source: medicalxpress
- 407
- December 19, 2017
late-life dementia Researches
ODS Medical’s Innovative Device Could Revolutionize Brain Cancer Surgery

The Montreal-based startup ODS Medical is developing a handheld surgical guidance tool to improve accuracy in cancer surgery. Based on a set of advanced optical techniques, such as Raman spectroscopy, intrinsic fluorescence and diffuse reflectance spectroscopy, together with sophisticated machine learning algorithms, their laser technology measure scattered light to provide more specific information about the molecular makeup of the targeted brain tissue.
- Source: mindsofmalady
- 558
- December 18, 2017
cancer surgery Company Insight tumor
Surgical Device Company Virtual Incision Raises $18 Million in Series B

Virtual Incision’s RASD weighs just two pounds and is designed to perform the procedure through a smaller incision, potentially reducing recovery time and mitigating the risk of surgical complications.
- Source: xtalks
- 563
- December 18, 2017
FDA medical device RASD Series
Atlas and OrbiMed back Boston’s Kyn in $49M round to pursue immunometabolism therapies

Kyn is led by an Atlas entrepreneur-in-residence Mark Manfredi, who was previously chief scientific officer at Raze Therapeutics (also an Atlas-funded startup). Raze raised a $24 million Series A in 2014, but the company appears to have wound down pretty quickly. The website is no longer active, and Manfredi said Raze still has some assets and collaborations, but no longer employs anyone. Atlas’ Bruce Booth says the underlying cancer metabolism biology was too complicated to warrant further investment. Before Raze, Manfredi was VP of oncology biology at Takeda.
- Source: Endpts
- 503
- December 18, 2017
cancer immunometabolism Market Views Series
Chi-Med Initiates Fruquintinib U.S. Clinical Trials

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) 1, 2 and 3, that has met its primary endpoint in several Phase II and III clinical trials in China for the treatment of colorectal, lung and gastric cancers. The clinical study in the U.S. is a multi-center, open-label, Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of fruquintinib in U.S. patients with advanced solid tumors. The first drug dose was administered earlier this month. Additional details about this study may be found at clinicaltrials.gov, using identifier NCT03251378.
- Source: chi-med
- 659
- December 18, 2017
cancer Clinical Trials Fruquintinib
How to Avoid Being Blocked

Social media has become one of biggest marketing tools on the Internet with Facebook being at the forefront of this marketing revolution. There are however, guidelines and policies on how to use Facebook and when these are violated, you stand the chance of having your account blocked.
- Source: Ddu
- 1,159
- December 15, 2017
Ddu College Facebook
Artificial Organs — We’re Entering an Era Where Transplants Are Obsolete

Around the world, lists of patients in need of an organ transplant are often longer than the lists of those willing (and able) to donate — in part because some of the most in-demand organs for transplant can only be donated after a person has died. By way of example, recent data from the British Heart Foundation (BHF) showed that the number of patients waiting for a heart transplant in the United Kingdom has grown by 162 percent in the last ten years.
- Source: futurism
- 467
- December 15, 2017
heart Researches transplant
Magnetically Guided Bacteria Move Confidently Within Strong Currents, May Soon Deliver Drugs Inside Body

Researchers at Queen’s University in Canada have managed to get a special type of bacteria to swim against a strong current, opening up the possibility of using the organisms as drug delivery vehicles. The team is using magnetotactic bacteria which have magnetic crystals within them and naturally orient themselves with the Earth’s magnetic field. By setting up the external magnetic field, the researchers were able to coax the bacteria to move in predictable ways and directions.
- Source: medgadget
- 420
- December 15, 2017
bacteria magnetotactic Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.